X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
Details:
Through the agreement, the company will focus on the supply and commercialization of DefenCath (taurolidine and heparin) for the treatment of catheter-related bloodstream infections.
Lead Product(s): Taurolidine,Heparin Sodium
Therapeutic Area: Infections and Infectious Diseases Product Name: Defencath
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: ARC Dialysis, LLC
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement April 08, 2024
Details:
CorMedix intends to use the net proceeds for the commercialization of Taurolock Hep500 (taurolidine), approved to be instilled into catheter-based devices for hemodialysis in order to maintain patency of the vascular access device.
Lead Product(s): Taurolidine,Heparin Sodium
Therapeutic Area: Nephrology Product Name: Taurolock Hep500
Highest Development Status: Phase IVProduct Type: Small molecule
Partner/Sponsor/Collaborator: RBC Capital Markets
Deal Size: $40.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering June 28, 2023
Details:
Alenura is a unique, combination product of alkalinised lidocaine and the glycosaminoglycan heparin. Alkalinised lidocaine penetrates the transitional epithelial cell layer and provides immediate pain relief.
Lead Product(s): Lidocaine,Heparin Sodium
Therapeutic Area: Urology Product Name: Alenura
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Vaneltix Pharma
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 22, 2023
Details:
DefenCath is a formulation of taurolidine and heparin with broad antimicrobial activity that is being investigated for use as a catheter lock solution, with the aim of reducing the risk of catheter-related bloodstream infections from central venous catheters (CVCs).
Lead Product(s): Taurolidine,Heparin Sodium
Therapeutic Area: Infections and Infectious Diseases Product Name: Defencath
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 21, 2023
Details:
DefenCath™ is a formulation of taurolidine and heparin with broad antimicrobial activity that is being investigated for use as a catheter lock solution, with the aim of reducing the risk of catheter-related bloodstream infections from central venous catheters (CVCs).
Lead Product(s): Taurolidine,Heparin Sodium
Therapeutic Area: Infections and Infectious Diseases Product Name: Defencath
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 16, 2023
Details:
DefenCath™ is a formulation of taurolidine and heparin with broad antimicrobial activity that is being investigated for use as a catheter lock solution, with the aim of reducing the risk of catheter-related bloodstream infections from central venous catheters (CVCs).
Lead Product(s): Taurolidine,Heparin Sodium
Therapeutic Area: Infections and Infectious Diseases Product Name: Defencath
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 01, 2023
Details:
Defencath is available in Europe and other territories under the brand name Neutrolin. It is used for catheter-related bloodstream infections in patients with end-stage renal disease receiving hemodialysis through a central venous catheter.
Lead Product(s): Taurolidine,Citric Acid,Heparin Sodium
Therapeutic Area: Infections and Infectious Diseases Product Name: Defencath
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 08, 2022
Details:
DefenCath is being developed as a catheter lock solution with an initial indication of use for the reduction of catheter-related bloodstream infections (CRBSIs) in patients with renal failure who are receiving chronic hemodialysis via a central venous catheter.
Lead Product(s): Taurolidine,Citric Acid,Heparin Sodium
Therapeutic Area: Infections and Infectious Diseases Product Name: Defencath
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 28, 2022
Details:
Under the terms of the agreement, Vaneltix will be responsible for the further development, manufacturing, regulatory affairs and commercialisation of AlenuraTM in collaboration with Hyloris.
Lead Product(s): Lidocaine,Heparin Sodium
Therapeutic Area: Urology Product Name: Alenura
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Hyloris Pharmaceuticals
Deal Size: $6.7 million Upfront Cash: Undisclosed
Deal Type: Collaboration December 17, 2021
Details:
The net proceeds of the Offering and Concurrent Private Placement will be used to support commercial efforts related to the recently launched products (Redesca™, Enerzair®, and Atectura®).
Lead Product(s): Heparin Sodium
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Redesca
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Desjardins Capital Markets
Deal Size: $10.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement November 24, 2021
Details:
TRIFERIC is indicated for the replacement of iron to maintain hemoglobin in adult patients with hemodialysis-dependent chronic kidney disease, Safety profile of drug is similar to placebo in controlled clinical trials in patients with end-stage kidney disease.
Lead Product(s): Ferric Pyrophosphate Citrate,Heparin Sodium
Therapeutic Area: Nephrology Product Name: Triferic
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 16, 2021
Details:
Under the terms of the contracts, the GPOs have listed Redesca™ and Redesca HP™, Valeo’s leading low molecular weight heparin (“LMWH”) biosimilar, as well as three other hospital products (Amikacin, Ethacrynate Sodium and Benztropine), for a 3-year period.
Lead Product(s): Heparin Sodium
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Redesca
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Group Purchasing Organizations
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement October 13, 2021
Details:
The trial, which will follow patients for one year, will assess whether treatment with the EKOS system in combination with anticoagulation is associated with a significant reduction in adverse events compared to anticoagulation alone, within seven days of randomization.
Lead Product(s): Heparin Sodium
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: Phase IVProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 04, 2021
Details:
Versiti has been granted three multi-center research contracts to coordinate nationwide clinical trials aimed at establishing optimal treatment plans for preventing blood clots in people with COVID-19. The contracts were awarded to Versiti by the University of Pittsburgh with funding by National Institutes of Health (NIH).
Lead Product(s): Heparin Sodium
Therapeutic Area: Hematology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: National Institutes of Health
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 29, 2021
Details:
Three clinical trial platforms spanning five continents in more than 300 hospitals have been working together to test whether there is a greater benefit of full doses of heparin to treat moderately ill hospitalized adults with COVID-19 compared to the lower heparin dose.
Lead Product(s): Heparin Sodium
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IVProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 22, 2021
Details:
Premier with Fresenius Kabi aims at supplying pre-filled, single-use IV bags of heparin sodium injection, USP to healthcare providers, helping to stabilize the long-term supply of a medication that is necessary when performing a number of hospital inpatient procedures.
Lead Product(s): Heparin Sodium
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Fresenius Kabi AG
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership November 18, 2020
Details:
Collectively known as ACTIV-4 Antithrombotics, the trials will provide critical insights that could help guide the care of patients with COVID-19, particularly those who suffer from life-threatening blood clots.
Lead Product(s): Heparin Sodium
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 10, 2020
Details:
U.S. FDA has accepted for filing the Company’s submitted New Drug Application (NDA) for Defencath™, its product candidate to be used as a catheter lock solution in hemodialysis patients for the prevention of catheter related blood stream infections (CRBSI).
Lead Product(s): Taurolidine,Citric Acid,Heparin Sodium
Therapeutic Area: Infections and Infectious Diseases Product Name: Defencath
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 31, 2020
Details:
The Company plans to use the net proceeds for general corporate purposes, including obtaining regulatory approval and commercialization of Defencath™ in the U.S., research and development, and working capital and capital expenditures.
Lead Product(s): Taurolidine,Citric Acid,Heparin Sodium
Therapeutic Area: Infections and Infectious Diseases Product Name: Defencath
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: SunTrust Robinson Humphrey
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Public Offering July 27, 2020
Details:
Based on research findings published in Antiviral Research, heparin may act as a decoy to prevent the virus from infecting human cells. Heparin can bind with the surface spike protein to potentially block the infection.
Lead Product(s): Heparin Sodium
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 16, 2020
Details:
Defencath is being developed as a catheter lock solution with an initial indication for use of preventing catheter-related bloodstream infections (CRBSIs) in patients with end-stage renal disease who are receiving hemodialysis via a central venous catheter.
Lead Product(s): Taurolidine,Citric Acid,Heparin Sodium
Therapeutic Area: Infections and Infectious Diseases Product Name: Defencath
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 08, 2020
Details:
Transaction enables Opocrin to become a leading global producer of active biologics including heparin and heparinoids.
Lead Product(s): Heparin Sodium
Therapeutic Area: Hematology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Cerus DMCC
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition April 29, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
